Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

 
ORIGINAL ARTICLE
Ahead of print publication  

Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study


1 Department of Pathology, Xinxiang Medical University, Xinxiang 453003, China
2 Department of Radiation Therapy, The Second Hospital of Jilin University, Changchun 130000, Jilin, China

Correspondence Address:
Xiao-Yu Yang,
Department of Radiation Therapy, The Second Hospital of Jilin University, No. 218 Ziqiang Road, Nanguan District, Changchun 130041, Jilin
China
Login to access the Email id

Source of Support: None, Conflict of Interest: None

 > Abstract 

Objective: The objective was to study the correlation between death-associated protein kinase (DAPK) promoter methylation and the clinicopathological and prognostic features in nonsmall cell lung cancer (NSCLC) patients.
Materials and Methods: A total of 117 NSCLC patients were recruited into our study between December 2012 and December 2014. Methylation-specific polymerase chain reaction was employed to detect the methylation status of DAPK in cancer tissues, peficancerous tissues, and serum samples of 117 NSCLC patients. In addition, serum samples of 115 healthy subjects were analyzed as controls. A literature search of English and Chinese databases, based on predefined criteria, identified published studies closely related to this study. Data were extracted, and meta-analysis was performed using STATA 12.0 software (STATA Corporation, College Station, TX, USA).
Results: O ur study results showed that DAPK promoter methylation frequency was significantly higher in NSCLC tissues compared to peficancerous normal tissues (58.1% vs. 12.8%, c2 = 52.45, P < 0.001). When serum samples were compared, DAPK methylation frequency in NSCLC patients was higher than the control group (27.4% vs. 0, c2 = 37.07, P < 0.001). Our meta-analysis results demonstrated that DAPK methylation frequency was lower in tumor node metastasis (TNM) stage I-II compared to TNM stage III-IV (relative risk [RR] =0.87, 95% confidence interval [CI] =0.76-0.99, P = 0.041). DAPK promoter methylation frequency in NSCLC patients with lymph node metastasis was significantly higher compared to the patients with no metastases (RR = 1.26, 95% CI = 1.04-1.52, P = 0.020). Finally, the 5-year survival rate was lower in NSCLC patient group with high frequency of DAPK methylation, compared to the patient group with unmethylated DAPK (RR = 0.71, 95% CI = 0.56-0.89, P = 0.004).
Conclusion: Our results showed that DAPK promoter methylation is tightly correlated with clinicopathological features of NSCLC and is associated with poor prognosis in patients.

Keywords: 5-year survival rate, clinicopathological features, cohort study, death-associated protein kinase, methylation, nonsmall cell lung cancer, prognosis



How to cite this URL:
Yang XY, Zhang J, Yu XL, Zheng GF, Zhao F, Jia XJ. Death-associated protein kinase promoter methylation correlates with clinicopathological and prognostic features in nonsmall cell lung cancer patients: A cohort study . J Can Res Ther [Epub ahead of print] [cited 2017 Jul 26]. Available from: http://www.cancerjournal.net/preprintarticle.asp?id=158197

.




 

 
Top
 
 
  Search
 
     Search Pubmed for
 
    -  Yang XY
    -  Zhang J
    -  Yu XL
    -  Zheng GF
    -  Zhao F
    -  Jia XJ
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

  >Abstract
  In this article

 Article Access Statistics
    Viewed778    
    PDF Downloaded19    

Recommend this journal